Ventures West

Aquinox Pharmaceuticals Inc., based in Vancouver, Canada, is a clinical-stage pharmaceutical company focused on discovering and developing oral drug candidates for the treatment of inflammatory diseases and cancer. Founded in 2004, the company is engaged in the development and commercialization of small molecule therapeutics. Its notable offerings include AQX-MN100, a drug targeting both cancer and inflammatory conditions, alongside a program aimed at SH2-containing inositol 5'-phosphatase inhibition for blood cell recovery. As of July 2020, Aquinox Pharmaceuticals operates as a subsidiary of Taro Pharmaceuticals Inc.

Aquinox Pharmaceuticals Inc., based in Vancouver, Canada, is a clinical-stage pharmaceutical company focused on discovering and developing oral drug candidates for the treatment of inflammatory diseases and cancer. Founded in 2004, the company is engaged in the development and commercialization of small molecule therapeutics. Its notable offerings include AQX-MN100, a drug targeting both cancer and inflammatory conditions, alongside a program aimed at SH2-containing inositol 5'-phosphatase inhibition for blood cell recovery. As of July 2020, Aquinox Pharmaceuticals operates as a subsidiary of Taro Pharmaceuticals Inc.

SWITCH Materials Inc. is a Canadian company founded in 2007, specializing in advanced materials that enable innovative smart window solutions for automotive applications, particularly for OEMs and Tier 1 suppliers. The company focuses on developing proprietary organic molecules that can switch optical properties on command, allowing for functionalities such as automatic darkening of sunroofs in sunlight to reduce heat and glare. Their technology integrates seamlessly into various applications, including automotive glass, architectural glass, and eyewear. SWITCH Materials also conducts extensive research and development in its laboratories and at Simon Fraser University’s 4D LABS, leveraging the expertise of materials scientists skilled in synthetic chemistry, polymer processing, and optics. The company aims to contribute to lower emissions and enhanced customer experiences in electric vehicle markets, as well as in custom solar management applications.

Aquinox Pharmaceuticals Inc., based in Vancouver, Canada, is a clinical-stage pharmaceutical company focused on discovering and developing oral drug candidates for the treatment of inflammatory diseases and cancer. Founded in 2004, the company is engaged in the development and commercialization of small molecule therapeutics. Its notable offerings include AQX-MN100, a drug targeting both cancer and inflammatory conditions, alongside a program aimed at SH2-containing inositol 5'-phosphatase inhibition for blood cell recovery. As of July 2020, Aquinox Pharmaceuticals operates as a subsidiary of Taro Pharmaceuticals Inc.

QuIC Financial Technologies, Inc. specializes in developing advanced simulation, risk calculation, and pricing platform solutions tailored for financial institutions and companies. The company offers a comprehensive product suite that includes the QuIC Engine, a high-performance desktop calculator capable of supercomputer-level processing, and QuIC Script, a vector computing language designed for formulating financial solutions. Additionally, QuIC Analytics delivers a range of analytical tools for various financial instruments, including derivatives, equities, and structured products. The company also provides QuIC Workbench for the customization and visualization of QuIC Script, along with integration products like QuIC Dispatch and QuIC Bridge to enhance interoperability with client systems. QuIC Financial Technologies further extends its services through product support, system integration, custom development, and consulting, addressing various risk management needs including market and credit risk. Founded in 1998 and headquartered in Vancouver, Canada, QuIC also maintains offices in London and New York.